| 1.7 0.03 (1.8%) | 09-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 2.13 | 1-year : | 2.32 |
| Resists | First : | 1.82 | Second : | 1.99 |
| Pivot price | 1.69  |
|||
| Supports | First : | 1.55 | Second : | 1.29 |
| MAs | MA(5) : | 1.67 |
MA(20) : | 1.71 |
| MA(100) : | 1.78 |
MA(250) : | 1.7 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 32.7 |
D(3) : | 29 |
| RSI | RSI(14): 48.1 |
|||
| 52-week | High : | 3.73 | Low : | 0.92 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ LXRX ] has closed below upper band by 48.5%. Bollinger Bands are 52.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.73 - 1.74 | 1.74 - 1.75 |
| Low: | 1.63 - 1.64 | 1.64 - 1.65 |
| Close: | 1.69 - 1.7 | 1.7 - 1.71 |
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Wed, 11 Sep 2024
HC Wainwright Reiterates Buy Rating for Lexicon Pharmaceuticals (NASDAQ:LXRX) - MarketBeat
Tue, 03 Sep 2024
Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences - StockTitan
Sun, 01 Sep 2024
Lexicon Pharmaceuticals, Inc. (LXRX): The Best Multibagger Penny Stock of 2025? - Yahoo Finance
Wed, 21 Aug 2024
Lexicon Pharmaceuticals Announces FDA Advisory Committee Meeting for Zynquista - StockTitan
Wed, 14 Aug 2024
Lexicon (LXRX) to Reprioritize Portfolio, Slash Jobs, Stock Up - Yahoo Finance
Sat, 03 Aug 2024
Lexicon Pharmaceuticals Needs To See Real Revenue Acceleration And Clinical/Regulatory Success - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 361 (M) |
| Held by Insiders | 1.8214e+008 (%) |
| Held by Institutions | 1.1 (%) |
| Shares Short | 22,350 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.9647e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -3 % |
| Return on Assets (ttm) | 360.8 % |
| Return on Equity (ttm) | -35.7 % |
| Qtrly Rev. Growth | 3.64e+006 % |
| Gross Profit (p.s.) | 325.27 |
| Sales Per Share | -73.5 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -0.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -196 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | -0.1 |
| Price to Book value | 0 |
| Price to Sales | -0.03 |
| Price to Cash Flow | 3.32 |
| Dividend | 0 |
| Forward Dividend | 2.539e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|